Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr233 Inhibitors

Olr233 inhibitors are a class of chemical compounds that specifically interact with and inhibit the activity of the Olr233 protein, which is a member of the olfactory receptor (Olr) family. These receptors belong to the G-protein coupled receptor (GPCR) superfamily, which plays a crucial role in cellular signaling pathways. The Olr233 receptor is known to be involved in recognizing specific odorant molecules, and its inhibition can disrupt the typical signaling cascade initiated upon odorant binding. The molecular structure of Olr233 inhibitors is typically characterized by functional groups that allow them to bind selectively to the Olr233 receptor's active or binding site, thereby preventing the receptor from undergoing the conformational change necessary to activate downstream signaling pathways.

The design and synthesis of Olr233 inhibitors require a deep understanding of the receptor's three-dimensional structure, especially the binding pocket's architecture, to create molecules with high specificity and affinity. Computational modeling, including techniques such as molecular docking and dynamics simulations, is often employed to predict the binding affinity of potential inhibitors and optimize their interactions with the receptor. Additionally, these inhibitors often undergo extensive structure-activity relationship (SAR) studies, where variations in their chemical structure are systematically explored to enhance inhibitory potency, selectivity, and stability. Research in this field may involve synthesizing various analogs, each with slight modifications in functional groups or molecular frameworks, to better understand how these changes affect the inhibition of Olr233 and to identify the most effective structural motifs for receptor inhibition.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

EGFR tyrosine kinase inhibitor, could disrupt signaling pathways potentially involving Olr233.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$109.00
$350.00
8
(0)

Immunomodulatory drug, might influence the cellular environment affecting Olr233 activity.

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$127.00
$178.00
2
(1)

Angiogenesis inhibitor, could affect pathways of vascular development relevant to Olr233.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Proteasome inhibitor, potentially impacts protein degradation pathways involving Olr233.

Lenalidomide

191732-72-6sc-218656
sc-218656A
sc-218656B
10 mg
100 mg
1 g
$49.00
$367.00
$2030.00
18
(1)

Immunomodulatory drug, may modulate the microenvironment and signaling related to Olr233.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

RAF kinase inhibitor, could disrupt multiple signaling pathways affecting Olr233.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Receptor tyrosine kinase inhibitor, might affect angiogenesis and growth signaling involving Olr233.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Src family kinase inhibitor, potentially alters signaling pathways that Olr233 is part of.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

JAK1/2 inhibitor, could modify cytokine signaling pathways relevant to Olr233.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$128.00
$638.00
7
(1)

mTOR inhibitor, may influence cell proliferation and survival pathways involving Olr233.